Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-05-22 Board/Management Inform…
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 22, 2025. It primarily announces the appointment of a new board member and the departure of another, as well as an amendment to the Certificate of Designations related to voting rights. The key content is about changes in the company's board of directors and amendments to corporate governance documents. There are no financial statements or detailed financial data presented. The document also includes a press release about the board appointment. Given the focus on board changes and governance amendments, this fits best under Board/Management Information (MANG).
2025-05-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 8, 2025. It announces the issuance of a press release regarding financial results for the quarter ended March 31, 2025. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length is 3649 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous filings and announcements that do not fit other categories.
2025-05-08 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 25, 2025, by Serina Therapeutics, Inc. It announces the entry into a material definitive agreement, specifically a Capital on Demand Sales Agreement for an at-the-market offering of common stock. The document includes detailed descriptions of the agreement terms, parties involved, and related exhibits such as the sales agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The primary content is an update on financing activities and capital structure changes. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length (7822 characters) supports it being a substantive filing rather than a brief announcement or certification. Confidence is high given the clear description of a financing agreement and the nature of Form 8-K disclosures.
2025-04-29 English
Regulatory Filings 2025
Regulatory Filings
2025-04-29 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement on Form S-3. It details an 'at the market offering' of common stock, including terms of the sales agreement, compensation to the sales agent, and risk factors. The document is a detailed offering document for capital raising purposes, describing the terms and conditions of a securities offering. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not merely an announcement or a brief summary. Therefore, the correct classification is CAP with high confidence.
2025-04-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.